Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
J Gastroenterol Hepatol. 2012 Jan;27(1):11-20. doi: 10.1111/j.1440-1746.2011.06925.x.
Ascites is a common complication of liver cirrhosis associated with a poor prognosis. The treatment of ascites requires dietary sodium restriction and the judicious use of distal and loop diuretics, sequential at an earlier stage of ascites, and a combination at a later stage of ascites. The diagnosis of refractory ascites requires the demonstration of diuretic non-responsiveness, despite dietary sodium restriction, or the presence of diuretic-related complications. Patients with refractory ascites require second-line treatments of repeat large-volume paracentesis (LVP) or the insertion of a transjugular intrahepatic portosystemic shunt (TIPS), and assessment for liver transplantation. Careful patient selection is paramount for TIPS to be successful as a treatment for ascites. Patients not suitable for TIPS insertion should receive LVP. The use of albumin as a volume expander is recommended for LVP of >5-6 L to prevent the development of circulatory dysfunction, although the clinical significance of post-paracentesis circulatory dysfunction is still debated. Significant mortality is still being observed in cirrhotic patients with ascites and relatively preserved liver and renal function, as indicated by a lower Model for End-Stage Liver Disease (MELD) score. It is proposed that patients with lower MELD scores and ascites should receive additional points in calculating their priority for liver transplantation. Potential new treatment options for ascites include the use of various vasoconstrictors, vasopressin V(2) receptor antagonists, or the insertion of a peritoneo-vesical shunt, all of which could possibly improve the management of ascites.
腹水是肝硬化的常见并发症,预后不良。腹水的治疗需要限制饮食中的钠摄入,并合理使用远端和袢利尿剂,在腹水早期阶段依次使用,在腹水晚期阶段联合使用。难治性腹水的诊断需要证明利尿剂无反应,尽管限制了饮食中的钠摄入,或存在利尿剂相关并发症。难治性腹水患者需要二线治疗,包括重复大量腹腔穿刺术(LVP)或经颈静脉肝内门体分流术(TIPS),并评估肝移植。TIPS 作为腹水治疗成功的关键是仔细选择患者。不适合 TIPS 插入的患者应接受 LVP。建议在 LVP 超过 5-6 L 时使用白蛋白作为容量扩张剂,以预防循环功能障碍的发生,尽管 LVP 后循环功能障碍的临床意义仍存在争议。在肝功能和肾功能相对保留的肝硬化伴腹水患者中仍观察到较高的死亡率,这表明终末期肝病模型(MELD)评分较低。有人提出,MELD 评分较低且伴有腹水的患者在计算肝移植优先权时应获得额外分数。腹水的潜在新治疗选择包括使用各种血管收缩剂、血管加压素 V2 受体拮抗剂或插入腹膜-膀胱分流术,所有这些都可能改善腹水的管理。